Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors

Cetuximab and panitumumab are two distinct monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor (EGFR), and both are widely used in combination with chemotherapy or as monotherapy to treat patients with RAS wild-type metastatic colorectal cancer. Although often considered interchangeable, the two antibodies have different molecular structures and can behave differently in clinically relevant ways. More specifically, as an immunoglobulin (Ig) G1 isotype mAb, cetuximab can elicit immune functions such as antibody-dependent cell-mediated cytotoxicity involving natural killer cells, T-cell recruitment to the tumor, and T-cell priming via dendritic cell maturation. Panitumumab, an IgG2 isotype mAb, does not possess these immune functions. Furthermore, the two antibodies have different binding sites on the EGFR, as evidenced by mutations on the extracellular domain that can confer resistance to one of the two therapeutics or to both. We consider a comparison of the properties of these two antibodies to represent a gap in the literature. We therefore compiled a detailed, evidence-based educational review of the known molecular, clinical, and functional differences between the two antibodies and concluded that they are distinct therapeutic agents that should be considered individually during treatment planning. Available data for one agent can only partly be extrapolated to the other. Looking to the future, the known immune activity of cetuximab may provide a r...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsPembro in combination with mFOLFOX7 or FOLFIRI was safe and tolerable in patients with mCRC.Clinical trial identificationNCT03374254; Release date: December 15, 2017.Editorial acknowledgementJacqueline Kolston, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA); Funded by Merck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA.Legal entity responsible for the studyMerck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA, and Array BioPharma.FundingMerck Sharp&Dohme Corp., a subsidiary of Merck&Co., Inc., Kenilworth, NJ, USA, and Array Bi...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe recurrence of mCRC after primary surgery and subsequent irinotecan-based therapies is strongly related to the immune microenvironment. Our IPM may have important implications for identifying subgroups of mCRC with low or high risk of recurrence, and give new insights in personal chemotherapy and immunotherapy for mCRC.Legal entity responsible for the studyCICAMS.FundingInitial Project 2018-1-4021 Beijing Municipal Health Commission.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThese results confirm that the GOLFIG regimen is a reliable therapy for pretreated mCRC patients and offer the rationale to design combination trials with immune-checkpoint blockade.Clinical trial identification1) GOLFIG-2 phase III trial; EudraCT: 2005-003458-81 2) GOLFIG-1 phase II trial; EudraCT no available, start July 2001.Legal entity responsible for the studyThe authors.FundingItalian Ministry of Education and Research (MIUR) (2009EHW394). Private grant from the “Associazione Culturale Federico II,” and from the “Associazione Riuniti Calabria Oncologia (ARCO)”.DisclosureAll authors...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundCanada has a publicly-funded healthcare system with a complex drug funding process. After Health Canada approval to market a drug, the pan-Canadian Oncology Drug Review (pCODR) makes a non-binding funding recommendation to the Canadian provinces (except Quebec), which each then decide whether the drug will be publicly funded. We identified the determinants of funding in this process.MethodsWe analyzed drugs for advanced lung (n  = 15), breast (n = 8), colorectal (CRC) (n = 7), melanoma (n = 10), and neuroendocrine (NET) (n = 3) cancer u...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsDevelopment of PD-1 B-cell vaccine was successful, showing no evidence of toxicity or autoimmunity in mice, rabbits and beagle dogs. The combination vaccines could provide improved outcomes in early stage disease sparing patients the toxicity of chemotherapy. A phase 1 clinical trial with the PD-1 vaccine is under planning.Legal entity responsible for the studyThe authors.FundingNIH; Imugene.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusion: Our results can explain why MSI and MSS CRC display different immunotherapy response, prognosis, and metastasis feature. Moreover, our predicted up-stream regulators in the regulatory networks may be promising therapeutic targets. PMID: 31450919 [PubMed - in process]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
A clinical trial is exploring whether a novel immunotherapy/antiangiogenic combination can serve as an effective second-line treatment for pleural mesothelioma. Early indications of the four-center, phase II clinical trial are positive. The combination involves nivolumab (Opdivo) , a well-known immunotherapy drug, and ramucirumab (Cyramza), a therapy drug that blocks the formation of blood vessels needed for new tumor growth. The Food and Drug Administration approved both drugs for the treatment of other cancers, but this clinical trial is the first to test them in combination for mesothelioma. The single-arm trial began i...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Condition:   Colorectal Cancer Interventions:   Drug: Chemotherapy;   Procedure: Radiofrequency ablation (RFA);   Drug: In situ immunotherapy Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Education | Erbitux | Immunotherapy